POINT Biopharma Global Inc.

When Thijs Spoor was weighing his next career move in 2022, one option stood out despite its humble appearance. While other opportunities offered larger funding rounds and flashier platforms, a small

The surge of interest in radiopharmaceuticals for both diagnostics and therapeutics is likely to prove very beneficial for Germany’s PentixaPharm GmbH which has a promising treatment for CNS lymphom

South Korea's SK Biopharmaceuticals Co., Ltd is looking to continue its growth story via a new diversification into the globally hot area of radiopharmaceuticals through a licensing agreement with C

Radionetics Oncology , a three-year-old start-up that has raised $82.5m to date, landed a sweet deal with Eli Lilly and Company , with the big pharma paying $140m up front for an exclusive right to b